Hanrahan Jessie 4

What Happened

• Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences (SLDB), was granted 54,925 restricted stock units (RSUs) reported as an award (code A) on January 29, 2026. The filing shows an acquisition price of $0.00 and a reported value of $0 for this derivative award. This was an award of contingent/derivative securities rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-01-29; Filing date (Form 4 accession): 2026-04-21 (appears late versus the usual 2‑business‑day Form 4 requirement).
• Transaction type/code: Award/Grant (A); instrument: RSUs (derivative).
• Shares involved: 54,925 RSUs granted; reported acquisition price: $0.00; total reported value: $0.
• Shares owned after transaction: Not specified in the provided extract — see the Form 4 for post‑transaction holdings.
• Relevant footnotes:
  • F1: Each RSU is a contingent right to receive one share of common stock.
  • F2: These RSUs stem from performance stock units (PSUs) originally granted June 11, 2024. PSUs vest in four 25% tranches upon achievement of board‑certified, non‑market, non‑financial performance milestones. The second milestone was certified met on Jan 29, 2026; shares tied to that milestone will vest only if the grantee remains in service on the Evaluation Date (anticipated in Q1 2027).

Context

• These awards are performance‑contingent RSUs, not immediate share deliveries. They only convert into actual shares if vesting and service conditions are satisfied at the later Evaluation Date. Such derivative grants are routine compensation and do not by themselves signal an immediate buy or sell by the insider.